• Mitesh J Borad, Mia D Champion, Jan B Egan, Winnie S Liang, Rafael Fonseca, Alan H Bryce, Ann E McCullough, Michael T Barrett, Katherine Hunt, Maitray D Patel, Scott W Young, Joseph M Collins, Alvin C Silva, Rachel M Condjella, Matthew Block, Robert R McWilliams, Konstantinos N Lazaridis, Eric W Klee, Keith C Bible, Pamela Harris, Gavin R Oliver, Jaysheel D Bhavsar, Asha A Nair, Sumit Middha, Yan Asmann, Jean-Pierre Kocher, Kimberly Schahl, Benjamin R Kipp, Barr FritcherEmily GEGDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America., Angela Baker, Jessica Aldrich, Ahmet Kurdoglu, Tyler Izatt, Alexis Christoforides, Irene Cherni, Sara Nasser, Rebecca Reiman, Lori Phillips, Jackie McDonald, Jonathan Adkins, Stephen D Mastrian, Pamela Placek, Aprill T Watanabe, Janine Lobello, Haiyong Han, Daniel Von Hoff, David W Craig, A Keith Stewart, and John D Carpten.
• Division of Hematology/Oncology Mayo Clinic, Scottsdale, Arizona, United States of America ; Mayo Clinic Cancer Center, Scottsdale, Arizona, United States of America ; Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
• PLoS Genet. 2014 Feb 1; 10 (2): e1004135.

AbstractAdvanced cholangiocarcinoma continues to harbor a difficult prognosis and therapeutic options have been limited. During the course of a clinical trial of whole genomic sequencing seeking druggable targets, we examined six patients with advanced cholangiocarcinoma. Integrated genome-wide and whole transcriptome sequence analyses were performed on tumors from six patients with advanced, sporadic intrahepatic cholangiocarcinoma (SIC) to identify potential therapeutically actionable events. Among the somatic events captured in our analysis, we uncovered two novel therapeutically relevant genomic contexts that when acted upon, resulted in preliminary evidence of anti-tumor activity. Genome-wide structural analysis of sequence data revealed recurrent translocation events involving the FGFR2 locus in three of six assessed patients. These observations and supporting evidence triggered the use of FGFR inhibitors in these patients. In one example, preliminary anti-tumor activity of pazopanib (in vitro FGFR2 IC50≈350 nM) was noted in a patient with an FGFR2-TACC3 fusion. After progression on pazopanib, the same patient also had stable disease on ponatinib, a pan-FGFR inhibitor (in vitro, FGFR2 IC50≈8 nM). In an independent non-FGFR2 translocation patient, exome and transcriptome analysis revealed an allele specific somatic nonsense mutation (E384X) in ERRFI1, a direct negative regulator of EGFR activation. Rapid and robust disease regression was noted in this ERRFI1 inactivated tumor when treated with erlotinib, an EGFR kinase inhibitor. FGFR2 fusions and ERRFI mutations may represent novel targets in sporadic intrahepatic cholangiocarcinoma and trials should be characterized in larger cohorts of patients with these aberrations.

43 keywords...

hide…